To find "fallen angels" I look to blue chip stocks that have already suffered crashes due to managem...
Top Picks 2017: Incyte
01/06/2017 6:00 am EST
This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests John McCamant, editor The Medical Technology Stock Letter.
Incyte (INCY) is poised for a strong performance in 2017 that will be driven by three major catalysts.
The first is that the firm's drug Jakafi will continue to be a compelling and sustainable high margin long-term growth driver for myeloproliferative disorders myelofibrosis (MF) and polycythemia vera (PV).
The recent failure from a competitor’s Phase III studies of momelotinib has removed a major uncertainty on the revenue front for INCY’s key commercial product. The potential upside of Jakafi sales in both MF and PV represents a significant growth opportunity.
Partner Eli Lilly (LLY) will sell INCY’s baricitinib in rheumatoid arthritis and we expect a strong commercial launch that will be driven by the potential to be another “Best in Class” drug.
Baricitinib has an excellent profile that includes once-a-day oral dosing versus the injectable biologics. In our view, baricitinib in rheumatoid arthritis represents a significant source of upside following its expected launch in early 2017, in both the U.S. and Europe.
Incyte’s novel cancer compound –- the IDO1 inhibitor epacadostat –- represents another growth opportunity. Its broad Phase II development program has maximized the opportunity in combination with PD1/PDL1 inhibitors.
To date we have only seen the IDO Phase I data in combination with Merck (MRK) for its drug Keytruda in melanoma.
INCY is currently enrolling a broad Phase II Program with all the major PD-1 players evaluating IDO/PD-1 combos in at least 14 tumor types in over 900 patients.
Jakafi growth, baricitinib approval, and Phase II IDO/PD-1 data -- in our view -- make INCY a catalyst rich stock in 2017, as well as a compelling M&A candidate. INCY is a buy under $100.
Related Articles on STOCKS
One of the main drivers of wealth creation is investors’ innate desire to save, invest and get...
Stefanie Kammerman, the Stock Whisperer, to tell you the Whisper of the Week: GE, SPY, QQQ, IWM, and...
Join Ken Calhoun each week for a new episode of Breakout Chart of the Week for stock swing traders a...